Health care utilization for psoriasis in the United States differs by race: An analysis of the 2001-2013 Medical Expenditure Panel Surveys - 13/12/17
Doi : 10.1016/j.jaad.2017.07.052
Alexander H. Fischer, MD, MPH a, Daniel B. Shin, PhD b, Joel M. Gelfand, MD, MSCE b, c, Junko Takeshita, MD, PhD, MSCE b, c, ⁎ 
a Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, Maryland
b Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania
c Department of Biostatistics Epidemiology and Informatics, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania
∗Correspondence to: Junko Takeshita, MD, PhD, MSCE, University of Pennsylvania Perelman School of Medicine, 3400 Civic Center Blvd, 7th fl, South Tower, Office 728, Philadelphia, PA 19104University of Pennsylvania Perelman School of Medicine3400 Civic Center Blvd, 7th fl, South Tower, Office 728PhiladelphiaPA19104
| Dr Takeshita is supported by National Institute of Arthritis and Musculoskeletal and Skin Diseases grant K23-AR068433. Dr Gelfand is supported by National Institute of Arthritis and Musculoskeletal and Skin Diseases grant K24-AR064310. |
|
| In the previous 12 months, Dr Gelfand has served as a consultant for Coherus (DSMB), Dermira, Janssen Biologics, Merck (DSMB), Novartis, Regeneron, Sanofi, and Pfizer, receiving honoraria, and he receives research grants (to the Trustees of the University of Pennsylvania) from AbbVie, Janssen, Novartis Corp, Regeneron, Sanofi, Celgene, and Pfizer, and received payment for continuing medical education work related to psoriasis that was supported indirectly by Eli Lilly and AbbVie. Dr Gelfand is a co–patent holder of resiquimod for the treatment of cutaneous T cell lymphoma. Dr Takeshita has received a research grant from Pfizer (to the Trustees of the University of Pennsylvania) and payment for continuing medical education work related to psoriasis that was supported indirectly by Eli Lilly. The other authors have no conflicts of interest to declare. |
© 2017
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 78 - N° 1
P. 200-203 - janvier 2018 Retour au numéro
Article précédent
- Cantharidin for treatment of facial molluscum contagiosum: A retrospective review
- Marla N. Jahnke, Sook Hwang, James L. Griffith, Tor Shwayder
- Prognosis, treatment, and disease outcomes in frontal fibrosing alopecia: A retrospective review of 92 cases
- Lauren C. Strazzulla, Lorena Avila, Xiaoxue Li, Kristen Lo Sicco, Jerry Shapiro
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?